Clinical trials
Lung Cancer, Small Cell clinical trials
Below are recruiting lung cancer, small cell clinical trials, each written for real people, not researchers. We’re tracking 1,516 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07668037Recruiting
Understanding long-term survival in NSCLC immunotherapy
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
BeijingAges 18 years+ - NCT07390565Enrolling by invitation
Study of YSQTG with immunotherapy and chemo for advanced lung cancer
This trial tests a Chinese herbal formula (YSQTG) combined with standard immunotherapy and chemotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding YSQTG improves outcomes for patients with a specific traditional Chinese medicine pattern.
Beijing, ChaoyangAges 18 years+ - NCT07373951Enrolling by invitation
Predicting cancer gene status from MRI scans in brain metastasis
This trial uses brain MRI scans and deep learning to predict whether non-small cell lung cancer that has spread to the brain has certain gene changes (EGFR or ALK). Knowing this may help guide treatment without needing additional tissue testing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07301983Enrolling by invitation
Testing a faster way to check lymph nodes in lung cancer surgery
This trial compares a new, quick test called OSNA to the standard method for checking lymph nodes in people with early-stage lung cancer who are having robotic surgery. The goal is to see if the new test works as well or better.
Pisa, PisaAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07214441Enrolling by invitation
BE+ program for lung cancer survivors
This trial tests a program called BE+ for people who have finished treatment for non-small cell lung cancer. It aims to see if the program is practical and helpful for improving health after treatment.
Columbia, South CarolinaAges 21 years+ - NCT07122882Enrolling by invitation
Genetic study of drug-resistant lung cancer
This trial looks at the genetic changes in non-small cell lung cancer (NSCLC) that has stopped responding to targeted therapy pills. It aims to understand why the cancer became resistant, which may help find better treatments.
TaoyuanAges 18 years+ - NCT06997458Enrolling by invitation
Liquid biopsy study for advanced lung or colon cancer
This study is testing a simple blood draw (liquid biopsy) to track advanced lung or colon cancer. It may help doctors understand the cancer better without needing repeated tissue biopsies.
Granada, AndalusiaAges 18 years+ - NCT06962449Enrolling by invitation
Study of Tislelizumab as First Treatment for Advanced Lung Cancer
This study looks at how well Tislelizumab works as the first treatment for advanced non-small cell lung cancer that has spread. It aims to understand which treatment strategies after Tislelizumab lead to the best survival outcomes for patients.
Shanghai, Shanghai MunicipalityAges Any age - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06876675Enrolling by invitation
Lorlatinib and high cholesterol in ALK+ lung cancer
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
BeijingAges 18–80 - NCT06816966Enrolling by invitationPhase 2
Chemo-immunotherapy with split radiation for extensive-stage lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and a special type of radiation given in split sessions for people with extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06747832Enrolling by invitationEarly Phase 1
INK cells after chemoradiation for small cell lung cancer
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Weifang, Shandong Province, China.Ages 18–75 - NCT06730685Enrolling by invitation
Sarcopenia and cachexia in lung cancer patients
This study looks at muscle loss (sarcopenia) and weight loss (cachexia) in people with lung cancer. Researchers want to understand these conditions better to improve care.
Næstved, Region SjællandAges 18 years+ - NCT06690216Enrolling by invitationPhase 1/Phase 2
PET scan study for PD-L1 in certain cancers
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
Jinan, ShandongAges 18 years+ - NCT06419179Enrolling by invitationPhase 2
Maintenance therapy for HRD-positive small-cell lung cancer
This trial tests whether a combination of two medications, durvalumab and olaparib, can help keep your extensive-stage small-cell lung cancer from coming back after standard first-line treatment. It is for people whose tumors have a specific genetic feature called HRD.
Cologne, North Rhine-WestphaliaAges 18–120 - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT06250777Enrolling by invitationPhase 2
T-DXd for HER2-mutant lung cancer with brain metastases
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
SeoulAges 20 years+
Hear when a new Lung Cancer, Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer, small cell?
- Yes. Clin2 currently lists 1,516 recruiting lung cancer, small cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer, small cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer, small cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.